

AMENDMENT TO THE CLAIMS

1. (Previously presented) A pharmaceutical composition comprising as an active ingredient a recombinant polyclonal antibody capable of reacting with or binding to proteins or epitopes derived from an inhaled, ingested, or airborne allergen, together with one or more pharmaceutically acceptable excipients, wherein said pharmaceutical composition is free of the allergen to which said recombinant polyclonal antibody is reactive or binds.

Claims 2-5: Cancelled.

6. (Previously presented) A pharmaceutical composition according to claim 1, comprising at least one pharmaceutically acceptable excipient capable of effecting topical application of said recombinant polyclonal antibody.

7. (Currently amended) A pharmaceutical composition according to ~~claim 5~~, claim 1 which is intended for topical administration to the oropharynx, nasal cavity, respiratory tract, gastrointestinal tract, conjunctival mucosa, vagina, urogenital mucosa, or for dermal application.

8. (Previously presented) A pharmaceutical composition according to claim 7, wherein the respiratory tract is selected from nasal, oral, pharyngeal, bronchial, or alveolar mucosa.

9. (Previously presented) A pharmaceutical composition according to claim 1, which is provided as a solution, dispersion, powder or in the form of microspheres.

10. (Previously presented) A pharmaceutical composition according to claim 1, wherein the recombinant polyclonal antibody is generated by phage display technology.

11. (Original) A pharmaceutical composition according to claim 10, wherein the recombinant polyclonal antibody is generated under such conditions that the immunoglobulin heavy chain variable region and light chain variable region gene segments are linked together in a parental library in order to allow for the bulk transfer of variable region light chain and heavy chain gene pairs from one vector to another, while allowing stable pairing of specific immunoglobulin variable region light chain and heavy chain gene segments as they are present upon selection from the parental library of immunoglobulin variable region light chain and heavy chain gene segment pairs encoding antibody molecules capable of reacting with or binding to an allergen.

12. (Original) A pharmaceutical composition according to claim 10, wherein the recombinant polyclonal antibody is generated under such conditions that the immunoglobulin heavy chain variable region and light chain variable region gene segments are linked together in order to allow for the bulk transfer of specific variable region light chain and heavy chain gene pairs from one vector to another, while allowing stable pairing of specific immunoglobulin variable region light chain and heavy chain gene segments as they are present in the original polyclonal immune response of an animal or human individual.

13. (Previously presented) A pharmaceutical composition according to claim 1, wherein the allergen is an allergen of house dust mites, dander from cat, dander from dog, dander from horse, tree pollen, grass pollen, or fungi.

14. (Previously presented) A pharmaceutical composition according to claim 1, comprising the recombinant polyclonal antibody in an amount in the range of 1 μ g to 1g per unit dosage form.

Claims 15-34: Canceled.

35. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgG antibody.

36. (Withdrawn) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgM antibody.

37. (Withdrawn) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgA antibody.

38. (Withdrawn) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is an IgD antibody.

39. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody has antibody molecules from a mixture of antibody classes.

40. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody binds said allergen with sufficient density to mediate the elimination of said allergen from a patient.

41. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody binds said allergen with a higher antibody density than a monoclonal antibody.

42. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody does not cross-react with endogenous self-antigens in a patient.

43. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody does not elicit an anaphylactic response in humans.

44. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is a fully human antibody.

45. (Previously presented) A pharmaceutical composition according to claim 1, wherein the variable region of said polyclonal antibody has a mutation.

46. (Previously presented) A pharmaceutical composition according to claim 1, wherein at least 85% of the antibody molecules in said composition are target-specific.

47. (Previously presented) A pharmaceutical composition according to claim 1, wherein at least 90% of the antibody molecules in said composition are target-specific.

48. (Previously presented) A pharmaceutical composition according to claim 1, wherein said polyclonal antibody is a complete antibody molecule or fragment thereof such as an F_{ab} fragment.

49. (Previously presented) A pharmaceutical composition according to any of claim 1, wherein said composition is provided as a microsphere, liposome, polyethylene glycol-conjugated complex, or complex of positively or negatively charged excipients with antibody molecules of the opposite charge, wherein said composition prolongs the clearance of said polyclonal antibody in a patient.


CONCLUSION

Applicants submit that the claims are in condition for allowance, and such action is requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

September 11, 2003


Kristina Bicker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

**RECEIVED
CENTRAL FAX CENTER**

SEP 12 2003

OFFICIAL